Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Orgenesis, Inc. (OTC: ORGS).

Full DD Report for ORGS

You must become a subscriber to view this report.


Recent News from (OTC: ORGS)

Orgenesis collaborates with Ben-Gurion University to develop and commercialize scaffold technology for cell transplantation
Orgenesis (NASDAQ: ORGS ) along with BGN Technologies and the National Institute for Biotechnology in the Negev, both affiliates of Ben-Gurion University of the Negev,  collaborates to develop and commercialize a novel alginate scaffold technology for cell transplantation, with an init...
Source: SeekingAlpha
Date: August, 23 2018 08:04
Orgenesis Announces Collaboration with Ben-Gurion University to Develop and Commercialize a Novel Scaffold Technology for Cell Transplantation
GERMANTOWN, Md. and BEER-SHEVA, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a manufacturer, service provider and developer of advanced cell therapies, along with BGN Technologies and the National Institute for Biotechnology in the Negev (NIBN), both affiliates...
Source: GlobeNewswire
Date: August, 23 2018 07:30
Orgenesis Announces that Dr. Ohad Karnieli, CEO of Atvio Biotech, a Wholly-Owned Subsidiary of Masthercell Global, will Present at the 2018 Bioprocessing Summit
GERMANTOWN, Md., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq: ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, today announced that Dr. Ohad Karnieli, Ph.D., MBA, Chief Executive Office...
Source: GlobeNewswire
Date: August, 15 2018 08:30
Orgenesis Announces Collaboration between Secant Group and Atvio Biotech, a Wholly Owned Subsidiary of Masthercell Global, to Develop and Commercialize Scaffold Technologies for Advanced Cell Therapies
Secant Group and Atvio Biotech to advance project under $1.8 million grant from the Israel-U.S. Binational Industrial R&D Foundation Orgenesis to utilize scaffold technology for its autologous cell therapy platform GERMANTOWN, Md., July 30, 2018 (GLOBE NEWSWIRE) -- Orgenesis In...
Source: GlobeNewswire
Date: July, 30 2018 08:30
Wired News - Biogen to Present Data from Alzheimer's Disease Clinical Development Portfolio at AAIC in Chicago
Stock Monitor: Orgenesis Post Earnings Reporting LONDON, UK / ACCESSWIRE / July 20, 2018 / If you want access to our free research report on Biogen Inc. (NASDAQ: BIIB ), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=B...
Source: ACCESSWIRE IA
Date: July, 20 2018 07:00
Orgenesis reports Q2 results
Orgenesis (NASDAQ: ORGS ): Q2 EPS of -$0.20 More news on: Orgenesis, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: July, 17 2018 11:08
Orgenesis Reports 73% Increase in Revenue for the Second Quarter of Fiscal 2018
GERMANTOWN, Md., July 17, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today reported financial results and provided a business update for the fiscal second quarter ended May 31, 2018. Fiscal Q2 2018 fi...
Source: GlobeNewswire
Date: July, 17 2018 10:52
Orgenesis Forms Strategic Partnership with Leading Healthcare Fund and Reports Planned Investment of up to $25 Million into MaSTherCell Subsidiary
Consolidates Global CDMO Business Including Belgian Subsidiary MaSTherCell S.A., Israeli Partner Atvio Biotech and Korean Partner Curecell Co. Announces Plans to Enter U.S. Market and Expand Global Manufacturing Capacity GERMANTOWN, Md., June 29, 2018 (GLOBE NEWSWIRE) -- Orgenesis...
Source: GlobeNewswire
Date: June, 29 2018 07:30
Orgenesis Inc. Added to Russell Microcap® Index
GERMANTOWN, Md., June 25, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, announced today that it has been added to the FTSE Russell Microcap® I...
Source: GlobeNewswire
Date: June, 25 2018 09:11
Orgenesis CDMO Partner Atvio Biotechnology's CEO to Present on Roundtable at the 2018 BIO International Convention
GERMANTOWN, Md., June 04, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, announced today that their Israeli Contract Development and Manufacturing O...
Source: GlobeNewswire
Date: June, 04 2018 12:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-075.615.575.795.536,723
2018-12-065.765.636.085.6328,520
2018-12-056.105.8456.105.727216,809
2018-12-046.105.8456.105.727216,809
2018-12-036.115.996.115.730124,868

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-03-1219,95939,88250.0451Short
2018-03-0917,04435,70547.7356Short
2018-03-087,14211,06564.5459Short
2018-03-072,6575,22650.8419Short
2018-03-064,89311,21943.6135Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ORGS.


About Orgenesis, Inc. (OTC: ORGS)

Logo for Orgenesis, Inc. (OTC: ORGS)

Orgenesis Inc. is a fully integrated biopharmaceutical company focused on developing a trans differentiation technology for diabetes and vertically integrating manufacturing that can optimize its abilities to scale up technologies for clinical trials and eventual commercialization, but also to apply disciplined execution to emerging technologies of other cell therapy markets in such areas as cell based cancer immunotherapies and neurodegenerative diseases. This integrated approach supports the Company s business philosophy of bringing to market significant life improving medical treatments.

 

Contact Information

 

 

Current Management

  • Vered Caplan / CEO
    • Ms. Caplan has been the Chairman of the Board and Chief Executive Officer since August , , prior to which she was Interim President and CEO since December , . Since , Ms. Caplan has been Chief Executive Officer of Kamedis Ltd., a company focused on utilizing plant extracts for dermatology purposes. From to , Ms. Caplan was Chief Executive Officer of GammaCan International Inc., a company focused on the use of immunoglobulins for treatment of cancer. During the previous five years, Ms. Caplan has been a director of the following companies: Opticul Ltd., a company involved with optic based bacteria classification Inmotion Ltd., a company involved with selfpropelled disposable colonoscopies Nehora Photonics Ltd., a company involved with noninvasive blood monitoring Ocure Ltd., a company involved with wound management Eve Medical Ltd., a company involved with hormone therapy for Menopause and PMS and Biotech Investment Corp., a company involved with prostate cancer diagnostics. Ms. Caplan has a M.Sc. in biomedical engineering from TelAviv University specializing in signal processing management for engineers from TelAviv University specializing in business development and a B.Sc. in mechanical engineering from the Technion Israel Institute of Technology specialized in software and cad systems.
  • Neil Reithinger / CFO, Treasurer, Secretary
    • Mr. Reithinger was appointed Chief Financial Officer, Secretary and Treasurer on August , . Mr. Reithinger is the Founder and President of Eventus Advisory Group, LLC, a private, CFOservices firm incorporated in Arizona, which specializes in capital advisory and SEC compliance for publiclytraded and emerging growth companies. He is also the President of Eventus Consulting, P.C., a registered CPA firm in Arizona. Prior to forming Eventus, Mr. Reithinger was COO amp CFO from March to December of New Leaf Brands, Inc., a branded beverage company, CEO of Nutritional Specialties, Inc. from April to October , a nationally distributed nutritional supplement company that was acquired by Nutraceutical International, Inc., Chairman, CEO, President and director of Baywood International, Inc. from January to March , a publiclytraded nutraceutical company and Controller of Baywood International, Inc. from December to January . Mr. Reithinger earned a B.S. in Accounting from the University of Arizona and is a Certified Public Accountant. He is a Member of the American Institute of Certified Public Accountants and the Arizona Society of Certified Public Accountants.
  • Vered Caplan / Chairman
    • Ms. Caplan has been the Chairman of the Board and Chief Executive Officer since August , , prior to which she was Interim President and CEO since December , . Since , Ms. Caplan has been Chief Executive Officer of Kamedis Ltd., a company focused on utilizing plant extracts for dermatology purposes. From to , Ms. Caplan was Chief Executive Officer of GammaCan International Inc., a company focused on the use of immunoglobulins for treatment of cancer. During the previous five years, Ms. Caplan has been a director of the following companies: Opticul Ltd., a company involved with optic based bacteria classification Inmotion Ltd., a company involved with selfpropelled disposable colonoscopies Nehora Photonics Ltd., a company involved with noninvasive blood monitoring Ocure Ltd., a company involved with wound management Eve Medical Ltd., a company involved with hormone therapy for Menopause and PMS and Biotech Investment Corp., a company involved with prostate cancer diagnostics. Ms. Caplan has a M.Sc. in biomedical engineering from TelAviv University specializing in signal processing management for engineers from TelAviv University specializing in business development and a B.Sc. in mechanical engineering from the Technion Israel Institute of Technology specialized in software and cad systems.
  • Yaron Adler / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
    • Mr. Adler was appointed as our director on April , . In Mr. Adler cofounded IncrediMail Ltd. and served as its Chief Executive Officer until and President until . In , prior to founding IncrediMail, Mr. Adler consulted Israeli startup companies regarding Internet products, services and technologies. Mr. Adler served as a Product Manager from to , and as a software engineer from to , at Tecnomatix Technologies Ltd., a software company that develops and markets production engineering solutions to complex automated manufacturing lines that fill the gap between product design and production, and which was acquired by UGS Corp. in April . In , Mr. Adler held a software engineer position at Intel Israel Ltd. He has a B.A. in computer sciences and economics from TelAviv University.
  • Hugues Bultot / Director
    • Mr. Bultot was appointed as a director on March , . Since April , Mr. Bultot has been the Chief Executive Officer of MaSTherCell SA, a Belgianbased contract development manufacturing organization in cell therapy, a company he cofounded in . Since January , Mr. Bultot is also the Founder and CEO of Univercells SA, a Belgianbased company focused on the development of the implementation of disruptive manufacturing science in order to make biologics accessible and affordable. Prior to founding MaSTherCell and Univercells, Mr. Bultot founded Artelis in with his partner, Jos Castillo, a Belgian biotech company that specialized in the development of disposable bioreactors for the vaccine and monoclonal antibodies industry and for cell therapy applications. Artelis was sold to ATMI in November , which was subsequently acquired by Pall Corporation NYSE: PLL in February . From until , Mr. Bultot was a director with Ascencio, a Euronextquoted real estate company where he was the head of the Audit Committee. Mr. Bultot founded Kitozyme in , a company developing vegetal chitosanbased applications for the nutrition, winemaking, cosmetics and medical device industry where he developed the entire manufacturing chain, led the strategy and the operations and concluded numerous codevelopment agreements and financial rounds.
  • Ashish Nanda / Director
    • Mr. Nanda was appointed a director on February , . Since , Mr. Nanda has been the Managing Director of Innovations Group, one of the largest outsourcing companies in the financial sector that employs close to , people working across various financial sectors. Prior to that, from to , Mr. Nanda held the position of Asst. Manager Corporate Banking at Emirates Banking Group where he was involved in establishing relationship with business houses owned by UAE nationals and expatriates in order to set up banking limits and also where he managed portfolios of USD billion. Mr. Nanda holds a Chartered Accountancy from the Institute of Chartered Accountants from India.
  • Dr. David Sidransky / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
    • Dr. Sidransky was appointed as a director on July , . Since , Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine s Department of Otolaryngology and Professor of Oncology, Cellular amp Molecular Medicine, Urology, Genetics, and Pathology at the John Hopkins University School of Medicine. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world in the field of oncology during the past decade, with over peer reviewed publications. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. Dr. Sidransky has served as Vice Chairman of the Board of Directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is serving, or has served on, the scientific advisory boards of MedImmune, LLC, Roche, Amgen Inc. and Veridex, LLC a Johnson amp Johnson diagnostic company , among others and is currently on the board of Galmed and Rosetta Genomics Ltd. and chairs the board of Advaxis and Champions Oncology, Inc. Dr. Sidransky served as Director from until of the American Association for Cancer Research AACR .
  • Guy Yachin / Director
    • Mr. Yachin has served as a director since April , . Mr. Yachin is the CEO of NasVax Ltd., a company focused on the development of improved immunotherapeutics and vaccines. Prior to joining NasVax, Mr. Yachin served as CEO of MultiGene Vascular Systems Ltd., a cell therapy company focused on blood vessels disorders, leading the company through clinical studies in the U.S. and Israel, financial rounds, and a keystone strategic agreement with Teva Pharmaceuticals Industries Ltd. He was CEO and founder of Chiasma Inc., a biotechnology company focused on the oral delivery of macromolecule drugs, where he built the company s presence in Israel and the U.S., concluded numerous financial rounds, and guided the company s strategy and operation for over six years. Earlier he was CEO of Naiot Technological Center Ltd., and provided seed funding and guidance to more than a dozen biomedical startups such as Remon Medical Technologies Ltd., Enzymotec Ltd. and NanoPass Technologies Ltd. He holds a BSc. in Industrial Engineering and Management and an MBA from the Technion Israel Institute of Technology.

Current Share Structure

  • Market Cap: $137,666,830 - 03/16/2018
  • Issue and Outstanding: 10,273,644 - 02/28/2018

 


Recent Filings from (OTC: ORGS)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 16 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 28 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: March, 19 2018
Filing Type: CERTFiling Source: edgar
Filing Date: March, 09 2018
Registration of certain classes of securities 12(b) of the Securities Exchange Act
Filing Type: 8-A12BFiling Source: edgar
Filing Date: March, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 28 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: February, 08 2018

 

 


Daily Technical Chart for (OTC: ORGS)

Daily Technical Chart for (OTC: ORGS)


Stay tuned for daily updates and more on (OTC: ORGS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ORGS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ORGS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ORGS and does not buy, sell, or trade any shares of ORGS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/